Latest News for: taar1

Edit

Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S. (Luye Pharma Group Ltd)

Public Technologies 15 Jan 2025
Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for LY03020, a dual TAAR1/5-HT2CR agonist intended to treat schizophrenia ... LY03020 targets both TAAR1 and 5-HT2CR.
Edit

Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China (Luye Pharma Group Ltd)

Public Technologies 06 Aug 2024
LY03020, a dual TAAR1/5-HT2CR agonist, is intended to treat schizophrenia and Alzheimer's disease psychosis (ADP) ... LY03020 targets both TAAR1 and 5-HT2CR. TAAR1 is primarily expressed on the presynaptic ...
  • 1

Most Viewed

×